Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Rain Oncology Inc | RAIN | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.21 | 20:00:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.21 | 1.21 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.82 - 10.51 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 1.21 | USD |
Rain Oncology Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 44.01M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Rain Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RAIN Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 1.02 | 1.27 | 0.99 | 1.18 | 298,229 | 0.19 | 18.63% |
| 1 Year | 7.39 | 10.51 | 0.82 | 1.40 | 703,359 | -6.18 | -83.63% |
| 3 Years | 22.10 | 23.90 | 0.82 | 4.39 | 290,038 | -20.89 | -94.52% |
| 5 Years | 22.10 | 23.90 | 0.82 | 4.39 | 290,038 | -20.89 | -94.52% |
Rain Oncology Description
| Rain Therapeutics Inc is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors' underlying genetics rather than histology. The company's product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, the company is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. |
